Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

4.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.4K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

6.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.0K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

2.9K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
2.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.9K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
  1. ホーム
  3. Pak4はmycをリン酸化し安定させ,急性骨髄性白血病を促進する.
  1. ホーム
  3. Pak4はmycをリン酸化し安定させ,急性骨髄性白血病を促進する.

関連する実験動画

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

261

PAK4はMYCをリン酸化し安定させ,急性骨髄性白血病を促進する.

Ting Xie1,2, Peipei Sun1,2, Hao Huang1,2

  • 1Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, Hubei, China.

Cell insight
|August 27, 2025

PubMed で要約を見る

まとめ
この要約は機械生成です。

急性骨髄性白血病 (AML) のMYCの安定化は,p21活性化キナーゼ4 (PAK4) によって引き起こされる. PAK4とMCL- 1を同時に抑制することで,シネジスティックな細胞死を引き起こすことで,AMLに対する有望な標的治療法となる.

キーワード:
急性骨髄性白血病MYC についてPAK4 についてリン酸化シンジェスティック・レタリティ

さらに関連する動画

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.0K
Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

7.6K

関連する実験動画

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

261
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.0K
Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

7.6K

科学分野:

  • 腫瘍学
  • 分子生物学
  • 癌 研究

背景:

  • MYCの調節不全は,急性骨髄性白血病 (AML) の主要な要因である.
  • MYCのタンパク質の安定性は,リン酸化とユビキチネーションを含む翻訳後の改変によって調節される.
  • 以前の研究では,MYCセリン67 (S67) のリン酸化がT細胞性急性リンパ性白血病 (T-ALL) の腫瘍性活性に決定的であることを確認した.

研究 の 目的:

  • MYC S67のリン酸化がAMLにおける役割を調査する.
  • AMLにおけるMYC S67のリン酸化を起こすキナーゼを特定する.
  • AMLにおけるMYCの安定化を狙った治療戦略を探求する.

主な方法:

  • AML細胞系におけるMYC S67のリン酸化を研究した.
  • MYC S67のリン酸化を触媒するキナーゼとして,p21活性化キナーゼ4 (PAK4) を特定した.
  • PAK4阻害剤 (KPT- 9274) とMCL- 1抗体 (S63845) を併用した.

主要な成果:

  • MYC S67のリン酸化はAMLに存在し,PAK4によって媒介される.
  • PAK4はMYCを直接結合し,S67をリン酸化し,MYCを安定させ,FBXW7依存のユビキチネーションを抑制する.
  • PAK4の抑制はMYCを不安定化し,AMLの増殖を減少させますが,補償的なMCL-1のアップレギュレーションはアポトーシスを制限します.
  • PAK4阻害とMCL- 1抗体が結合すると,AML細胞のシネジスト的致死性が生じます.

    • 結論:

    • PAK4媒介によるMYCの安定化は,AMLにおける重要なメカニズムである.
    • PAK4を標的にするとMYCが不安定になり,AMLの成長が抑制されます.
    • PAK4阻害剤とMCL-1抗剤を併用した治療は,AMLに対する有意な治療の可能性を示しています.